WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases

This study aims to evaluate the safety and efficacy of hippocampal-sparing WBRT combined with SRS as first-line treatment for SCLC patients with brain metastases.

Trial Details

NCT ID
NCT06243003
Phase
PHASE1 / PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • HA-WBRT plus SBRT
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group(ECOG) performance status score 0-2;
  • Small cell lung cancer confirmed by histopathology or cytology;
  • Complete baseline imaging data (including brain enhanced MRI/CT, positron emission tomography(PET/CT) or chest enhanced CT+ bone scan + neck and ab…
  • Patients with initial diagnosis of ES-SCLC with brain metastases who planned to receive at least 4 cycles of standard platinum-based doublet chemot…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →